Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tozadenant - Acorda Therapeutics

Next Previous
Drug Profile

Tozadenant - Acorda Therapeutics

Alternative Names: A2a-(3); RO4494351; RO4494351-000; RO4494351-002; SYN-115

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Acorda Therapeutics
  • Class Amides; Antiparkinsonians; Benzothiazoles; Carboxylic acids; Morpholines; Piperidines; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver disorders; Parkinson's disease

Most Recent Events

  • 20 Nov 2017 Biotie Therapies terminates a phase I trial in Liver disorders (In volunteers) in USA based on previously disclosed agranulocytosis and associated serious adverse events (PO) (NCT03212313)
  • 20 Nov 2017 Biotie Therapies terminates the phase III TOZ-PD trial in Parkinson's disease (Adjunctive treatment) in USA, Canada, Spain, Germany, Czech Republic due to previously disclosed agranulocytosis, associated serious adverse events and safety concerns (PO) (NCT02453386)
  • 20 Nov 2017 Biotie Therapies terminates a phase I trial in Healthy volunteers in Canada based on previously disclosed agranulocytosis, associated serious adverse events and safety concerns (PO) (NCT03200080)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top